Immunovaccine’s Ovarian Cancer Therapy Gains Orphan Drug Status in EU

The European Medicines Agency granted an orphan drug designation to Immunovaccine’s immunotherapy candidate for ovarian cancer.

Immunovaccine’s therapy, DPX-Survivac, activates an immune response to survivin — a protein found in more than 90 percent of ovarian cancer patients’ tumors.

The EMA also granted orphan drug status to the company’s candidate for the treatment of ovarian cancer, no matter the stage of progression.